$5 Million Upfront Payment; Additional Milestones to Follow
Potential Participation of Taisho in Celltrion’s Global Phase 3 Trial

On July 31, Korean-American biotech company Kaigen announced that it has signed a license agreement with Japanese pharmaceutical firm Taisho Pharmaceutical for the exclusive development and commercialization of the next-generation neonatal Fc receptor (FcRn) inhibitor ‘KG006’ in Japan.


Under the agreement, Taisho Pharmaceutical will have exclusive rights to conduct clinical development, obtain regulatory approval, and commercialize KG006 within Japan. Kaigen will receive a $5 million upfront payment. Additionally, Kaigen may receive up to $22 million and 57.5 billion yen (approximately $351 million) in development, approval, and sales milestone payments depending on future clinical development, regulatory approval, and cumulative sales targets reached. The company will also be eligible to receive tiered royalties based on net sales of the product in Japan.


ChatGPT Generated Image

ChatGPT Generated Image

View original image

This agreement also serves to complement Kaigen’s existing global partnership with Celltrion. Celltrion retains the global development and commercialization rights for KG006 in all regions except Japan and Greater China. There is speculation that a trilateral cooperation system could be established in the future, in which Taisho Pharmaceutical participates in a global multi-regional Phase 3 clinical trial (MRCT) led by Celltrion.



Shin Minjae, CEO of Kaigen, stated, “With Taisho Pharmaceutical joining as the optimal partner for the Japanese market, following our global development collaboration with Celltrion, a powerful ‘one team’ has been established.” He added, “We are committed to developing KG006 to become the ‘best-in-class’ therapy in the global FcRn therapeutics market.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing